Method of treating glioma
Methods of treating glioma are provided. Aspects of the invention include administering a therapeutically-effective amount of an agent that inhibits the activity of one or more neuronal activity-regulated proteins selected from: neuroligin-3, brain-derived neurotrophic factor (BDNF), or brevican, to a patient with a glioma. In certain embodiments, the subject methods involve treating a neurological dysfunction, reducing invasion of a glioma cell into brain tissue, and/or reducing the growth rate of a glioma in the patient. Also provided herein are methods for identifying an agent that modulates the mitotic index of a glial cell, and methods for stimulating the proliferation of a glial cell. Kits that find use in practicing the subject methods are also provided.
1. A method of reducing a neurological dysfunction in a patient with a glioma tumor, the method comprising:
administering to the patient a therapeutically-effective amount of an ADAM10 inhibitor INCB7839 that reduces secretion of neuroligin-3 in the glioma tumor; and
measuring a level of secreted neuroligin-3 in cerebrospinal fluid (CSF) from the patient.
2. The method according to claim 1 , wherein the neurological dysfunction comprises pain, numbness, seizures, neuromuscular dysfunction, cognitive impairment, or personality changes.
3. The method according to claim 1 , wherein INCB7839 is administered to the subject orally, intravenously, locally or intrathecally.
4. The method according to claim 1 , wherein INCB7839 is formulated for sustained release.
5. The method according to claim 1 , wherein said administering INCB7839 reduces secreted neuroligin-3 by at least 50% as compared to the secreted form of neuroligin-3 in the patient without treatment with the ADAM10 inhibitor INCB7839.
6. The method according to claim 1 , wherein said secreted neuroligin-3 is measured using an immunological assay.
7. The method according to claim 6 , wherein the immunological assay is a Western-Blot assay.
8. A method of preventing a glioma tumor cell from invading a brain tissue in a patient, the method comprising:
administering to the patient a therapeutically-effective amount of an ADAM10 inhibitor INCB7839 that reduces secretion of neuroligin-3; and
measuring a level of secreted neuroligin-3 in cerebrospinal fluid (CSF) from the patient.
9. The method according to claim 8 , wherein INCB7839 is administered to the subject orally, intravenously, locally or intrathecally.
10. The method according to claim 8 , wherein INCB7839 is formulated for sustained release.
11. A method of reducing a growth rate of a glioma tumor cell in a patient, the method comprising:
administering to the patient a therapeutically-effective amount of an ADAM10 inhibitor INCB7839 that reduces secretion of neuroligin-3; and
measuring a level of secreted neuroligin-3 in cerebrospinal fluid (CSF) from the patient.
12. The method according to claim 11 , wherein INCB7839 is administered to the subject orally, intravenously, locally or intrathecally.
13. The method according to claim 11 , wherein INCB7839 is formulated for sustained release.
14. A method for treating a glioma tumor in a subject, the method comprising:
administering to the subject a therapeutically-effective amount of an ADAM10 inhibitor INCB7839 that reduces secretion of neuroligin-3.
15. The method according to claim 14 , wherein INCB7839 is administered to the subject orally, intravenously, locally or intrathecally.
16. The method according to claim 14 , wherein INCB7839 is formulated for sustained release.